Aviptadil
Investigational — VIP — not FDA-approved.
What it's for
Aviptadil is a synthetic form of vasoactive intestinal peptide.
What it does for the body
It has been studied for pulmonary arterial hypertension, ARDS, and COVID-related respiratory failure. Not FDA-approved for these uses. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
VIP receptors (lock-and-key landing spots on cells) on alveolar cells and vessels mediate anti-inflammatory and blood-vessel–widening signaling hypothesized to protect lung tissue. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Aviptadil is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Immune research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Aviptadil — FDA.gov search
- ClinicalTrials.gov search: Aviptadil — U.S. clinical trials registry
- Drugs@FDA search: Aviptadil — FDA drug database (if approved)
- PubMed search: Aviptadil — NCBI PubMed
- PubMed Central search: Aviptadil — NCBI PMC